Publications

• Perioperative Management and Outcomes of Hyperthyroid Patients Unable to Tolerate Antithyroid Drugs.

  (Hsieh LB, Yen TWF, Dream S, Patel D, Evans DB, Wang TS.) World J Surg. 2020 Nov;44(11):3770-3777 PMID: 32572525 SCOPUS ID: 2-s2.0-85086709261 06/24/2020

• Total Neoadjuvant Therapy for Operable Pancreatic Cancer.

  (Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S.) Ann Surg Oncol. 2020 Sep 30 PMID: 33000372 SCOPUS ID: 2-s2.0-85091728559 10/02/2020

• Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.

  (Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S.) Surgery. 2020 09;168(3):440-447 PMID: 32641278 SCOPUS ID: 2-s2.0-85087345792 07/10/2020

• Commentary: Surgery for locally advanced pancreatic cancer after neoadjuvant therapy.

  (Evans DB.) Surgery. 2020 Aug 28 PMID: 32868112 09/02/2020

• Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer.

  (Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY.) Surgery. 2020 Aug 18 PMID: 32826069 SCOPUS ID: 2-s2.0-85089521842 08/23/2020

• Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy.

  (Kim RY, Evans DB, Christians KK.) Hepatobiliary Surg Nutr. 2020 Aug;9(4):497-500 PMID: 32832502 PMCID: PMC7423551 08/25/2020

• The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.

  (Evans DB.) Ann Surg. 2020 Jul 09 PMID: 32657915 07/14/2020

• Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.

  (Taskin OC, Clarke CN, Erkan M, Tsai S, Evans DB, Adsay V.) J Gastrointest Oncol. 2020 Jun;11(3):548-558 PMID: 32655934 PMCID: PMC7340800 SCOPUS ID: 2-s2.0-85090285071 07/14/2020

• Treatment sequencing for pancreatic neuroendocrine tumors: daring to challenge the status quo.

  (Clarke CN, Evans DB.) J Gastrointest Oncol. 2020 Jun;11(3):545-547 PMID: 32655933 PMCID: PMC7340804 SCOPUS ID: 2-s2.0-85090280297 07/14/2020

• Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.

  (Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A.) Ann Surg. 2020 May 08 PMID: 32398486 PMCID: PMC7648727 05/14/2020

• Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma

  (Rowan DJ, Hartley CP, Aldakkak M, Christians KK, Evans DB, Tsai S, Hagen CE.) Annals of Diagnostic Pathology. June 2020;46 SCOPUS ID: 2-s2.0-85081260042 06/01/2020

• Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy.

  (Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S.) Front Oncol. 2020;10:500 PMID: 32363161 PMCID: PMC7180175 SCOPUS ID: 2-s2.0-85084152103 05/05/2020